StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.75−0.06 (-0.12%)

Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%

Qiagen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was $659.60M, up 119.2% from the year before. Over ten years it grew 5.9% a year on average. The highest annual figure on record is $845.02M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$659.60M+119.2%
FY2024Dec 31, 2024$300.98M-51.1%
FY2023Dec 31, 2023$615.27M-16.8%
FY2022Dec 31, 2022$739.86M-12.4%
FY2021Dec 31, 2021$845.02M+42.9%
FY2020Dec 31, 2020$591.45M+188.1%
FY2019Dec 31, 2019$205.32M-56.6%
FY2018Dec 31, 2018$473.02M+27.9%
FY2017Dec 31, 2017$369.87M+18.6%
FY2016Dec 31, 2016$311.88M-15.9%
FY2015Dec 31, 2015$370.97M+2.3%
FY2014Dec 31, 2014$362.48M+38.0%
FY2013Dec 31, 2013$262.69M-28.6%
FY2012Dec 31, 2012$367.71M+37.7%
FY2011Dec 31, 2011$266.97M-19.4%
FY2010Dec 31, 2010$331.32M+44.8%
FY2009Dec 31, 2009$228.78M+21.5%
FY2008Dec 31, 2008$188.28M–

More Qiagen figures

See a number that looks wrong?